

# **Hutchmed (13 HK)**

# Fruquintinib to unlock the global potential in mCRC indication

- Superior improvement in overall survival in mCRC. HCM released data of the global Ph3 FRESCO-2 trial of fruquintinib in refractory metastatic colorectal cancer (CRC) at ESMO 2022 (link). The study enrolled 691 heavily pre-treated mCRC patients globally (71% from Europe, 18% from the US, 8% from Japan and 3% from AU). The median line of prior treatments was five, and 91% and 48% of patients had previously received TAS-102 and regorafenib, respectively. The study met the primary endpoint of OS. With 11 months of follow-up, the mOS was 7.4 months for the 461 patients in the fruquintinib + BSC arm, compared to 4.8 months for the 230 patients in the placebo + BSC arm. Fruquintinib delivered 2.6 months of mOS improvement and 34% reduction in risk of death (HR=0.66, p<0.001), which was superior to other approved medicines. TAS-102 extended mOS by 2.0 months and reduced the risk of death by 31% (link), while less effectively, regorafenib improved the mOS by 1.4 months and reduced the risk of death by 23% (*link*). Notably, FRESCO-2 trial enrolled more heavily pre-treated patients, with 73% of patients received >3 lines of prior treatment, compared to 60% in TAS-102's and 49% in regorafenib' studies. In FRESCO-2 study, the mPFS improvement was 1.9 months (3.7 vs 1.8 months; HR=0.32; p<0.001), meeting the key secondary endpoint. The global FRESCO-2 results were consistent with the China FRESCO study (mOS increased by 2.7 months with HR of 0.65; mPFS increased by 1.9 months with HR of 0.26; <u>link</u>) which led to the approval in China in 2018.
- Favourable safety profile. In FRESCO-2 trial, Gr≥3 TEAEs occurred in 62.7% of patients in the fruguintinib arm (vs 50.4% in the control arm), and the most common Gr≥3 TEAEs included hypertension (13.6% vs 0.9%) and asthenia (7.7% vs 3.9%). As for cross-trial comparisons, Gr≥3 TEAEs occurred in 69% of patients treated with TAS-102 (vs 52% in control group), while as high as 38% and 21% of patients treated with TAS-102 had Gr≥3 neutropenia and leukopenia, respectively (*link*). Gr≥3 TRAEs in FRESCO-2 trial were 36.0% vs 11.3% in the two arms, while the Gr≥3 TRAEs were 54% vs 14% in regorafenib's trial (*link*).
- To pursue global commercial approvals with BLA filings in the near term. By combining the data of China FRESCO and global FRESCO-2 trials, the Company will file BLA of fruquintinib for 3L+ CRC in the US, followed by the fillings in the Europe and Japan. With US Fast Track Designation, fruquintinib is entitled for rolling submission. We expect the pre-NDA meeting with US FDA in this Oct. HCM is open to cooperate with global partners for developing and marketing fruquintinib overseas.
- Maintain BUY. We are positive on fruquintinib's global approvals. We revised our TP from HK\$36.06 to HK\$36.43 based on a 14-year DCF valuation (WACC: 10.73%, terminal growth rate: 2%).

### **Earnings Summary**

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E				
Revenue (US\$ mn)	228	356	440	516	667				
YoY growth (%)	11.3	56.2	23.4	17.3	29.4				
Net profit (US\$ mn)	(115.5)	(167.0)	(298.3)	(271.9)	(92.2)				
EPS (Reported) (US\$)	(0.18)	(0.25)	(0.38)	(0.35)	(0.14)				
R&D expenses (US\$)	(175)	(299)	(330)	(350)	(267)				
CAPEX (US\$ mn)	(8)	(16)	(50)	(15)	(10)				
Source: Company data, Bloomberg, CMBIGM estimates									

## **BUY (Maintain)**

**Target Price** HK\$36.43 (Previous TP HK\$36.06) Up/Downside 85.3% **Current Price** HK\$19.66

#### China Healthcare

Jill WU. CFA (852) 3900 0842 jillwu@cmbi.com.hk

# **Andy WANG** (852) 3657 6288

andywang@cmbi.com.hk

Stock Data	
Mkt Cap (HK\$ mn)	1,966.0
Avg 3 mths t/o (HK\$ mn)	20.4
52w High/Low (HK\$)	61.00/14.86
Total Issued Shares (mn)	100.0

Source: FactSet

Ctack Data

#### Shareholding Structure 38.5% CK Hutchison Holdings The Capital Group 10.8%


Source: HKEx

## **Share Performance**

	Absolute	Relative
1-mth	-9.6%	-3.2%
3-mth	25.2%	40.0%
6-mth	-18.4%	-9.6%

Source: FactSet

## 12-mth Price Performance



Source: FactSet



Figure 1: Risk-adjusted DCF valuation

DCF Valuation (in US\$ mn)	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	(332)	(305)	(124)	95	231	391	550	713	803	859	900	818	841	866
Tax rate	0%	0%	0%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	(332)	(305)	(124)	81	197	332	468	606	682	730	765	695	715	736
+ D&A	8	17	16	15	14	13	13	12	12	11	11	11	11	11
- Change in working capital	21	(10)	(15)	(32)	(67)	(47)	(49)	(40)	(34)	(26)	(18)	(7)	22	(9)
- Capex	(50)	(15)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
FCFF	(352)	(313)	(134)	55	133	289	421	568	650	705	748	689	737	728
Terminal value														8,509
Present value of enterprise (US\$ mn)	3.435													

(629) Net debt (US\$ mn) Equity value (US\$ mn) 4,064 31,497 Equity value (HK\$ mn) No. of outstanding shares (mn) 865 36.43 DCF per share (HK\$) Terminal growth rate 2.0% WACC 10.73% Cost of Equity 13.5% Cost of Debt 5.0%

**Equity Beta** 1.00 3.0% Risk Free Rate Market Risk Premium 10.5% 30.0% Target Debt to Asset ratio 15.0% Effective Corporate Tax Rate

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (HK\$)

				WACC		
		9.73%	10.23%	10.73%	11.23%	11.73%
	4.00%	52.04	46.79	42.34	38.55	35.27
	3.50%	49.30	44.59	40.56	37.08	34.05
Terminal growth rate	3.00%	43.21	39.60	36.43	33.64	31.16
	2.50%	41.68	38.32	35.35	32.72	30.38
	2.00%	40.32	37.17	34.39	31.90	29.68

Source: CMBIGM estimates

Figure 3: CMBIGM estimates revision

	New				Old		Diff (%)			
US\$ mn	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	
Revenue	440	516	667	440	516	680	0%	0%	-2%	
Gross Profit	126	177	275	126	177	283	0%	0%	-3%	
Operating Profit	(332)	(305)	(124)	(332)	(305)	(124)	N/A	N/A	N/A	
Net profit	(326)	(299)	(120)	(326)	(299)	(119)	N/A	N/A	N/A	
EPS (US\$)	(0.38)	(0.35)	(0.14)	(0.38)	(0.35)	(0.14)	N/A	N/A	N/A	
Gross Margin	28.70%	34.27%	41.15%	28.70%	34.27%	41.60%	0.00 ppt	0.00 ppt	-0.45 ppt	

Source: Company data, Bloomberg, CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

US\$ mn		CMBIGM			Consensus		Diff (%)			
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	
Revenue	440	516	667	408	469	666	8%	10%	0%	
Gross profit	126	177	275	130	173	288	-3%	2%	-5%	
Operating profit	(332)	(305)	(124)	(412)	(436)	(353)	N/A	N/A	N/A	
Net profit	(326)	(299)	(120)	(377)	(403)	(307)	N/A	N/A	N/A	
EPS (US\$)	(0.38)	(0.35)	(0.14)	(0.45)	(0.69)	(0.60)	N/A	N/A	N/A	
Gross margin	28.70%	34.27%	41.15%	31.89%	36.91%	43.25%	-3.18 ppt	-2.63 ppt	-2.09 ppt	

Source: Bloomberg, CMBIGM estimates



# **Financial Summary**

Total equity and liabilities

INCOME STATEMENT	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (US\$ mn)						
Revenue	205	228	356	440	516	667
Cost of goods sold	(160)	(189)	(258)	(313)	(339)	(393)
Gross profit	45	39	98	126	177	275
Operating expenses	(191)	(236)	(426)	(458)	(482)	(399)
Selling expense	(14)	(11)	(38)	(53)	(52)	(65)
Admin expense	(39)	(50)	(89)	(75)	(80)	(67)
R&D expense	(138)	(175)	(299)	(330)	(350)	(267)
Operating profit	(146)	(197)	(328)	(332)	(305)	(124)
Other income	2	5	2	0	0	0
Other expense	(0)	(0)	(13)	0	0	0
Gain/loss on financial assets at FVTPL	4	2	1	3	3	2
Other gains/(losses)	0	0	121	0	0	0
Pre-tax profit	(141)	(190)	(216)	(328)	(302)	(122)
Income tax	(3)	(5)	(12)	0	0	Ó
Others	41	79	61	30	30	30
Minority interest	(2)	(10)	(28)	(28)	(28)	(28)
Net profit	(104)	(116)	(167)	(298)	(272)	(92)
BALANCE SHEET	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (US\$ mn)						
Current assets	317	531	1,212	840	548	436
Cash & equivalents	121	236	378	329	319	188
Account receivables	43	48	84	66	81	95
Inventories	16	20	36	30	33	38
Financial assets at FVTPL	96	200	634	334	34	34
Other current assets	40	28	81	81	81	81
Non-current assets	148	193	161	232	<b>261</b>	284
PP&E	21	24	41	83	81	75
Deferred income tax	1	2	9	9	9	9
Investment in JVs & assos	99	140	76	106	136	166
Other non-current assets	27	28	33	33	33	33
Total assets	465	<b>724</b>	1,373	1,072	808	<b>720</b>
Current liabilities	113	158	312	309	318	322
Short-term borrowings	0	0	27	27	27	27
Account payables	24	32	41	39	47	51
Tax payable	2	1	16	16	16	16
Other current liabilities	87	126	228	228	228	228
Non-current liabilities	39	47	220 <b>21</b>	220 <b>21</b>	220 <b>21</b>	220 21
Long-term borrowings	27	<b>27</b>	0	0	0	0
Obligations under finance leases	3	6	7	7	7	7
Deferred income	0	0	0	0	0	0
Other non-current liabilities	9	13	14	14	14	14
Total liabilities	152	205	333	331	339	343
Share capital	67	73	86	86	86	86
Capital surplus	515	822	1,505	1,505	1,505	1,505
Retained earnings	(290)	(416)	(610)	(936)	(1,236)	(1,356)
Other reserves	(4)	(416)	(610)	(936)	(1,236)	(1,330)
Other reserves  Total shareholders equity	(4) <b>288</b>	4 484	987	661	361	242
	<b>266</b> 25	<b>464</b> 35				135
Minority interest	25	30	53	80	108	135

313

519

1,040

741

469

377



CASH FLOW	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (US\$ mn)						
Operating						
Profit before taxation	(141)	(190)	(216)	(328)	(302)	(122)
Depreciation & amortization	5	6	7	8	17	16
Tax paid	(3)	(5)	(12)	0	0	0
Change in working capital	17	29	33	21	(10)	(15)
Others	42	97	(16)	0	0	0
Net cash from operations	(81)	(62)	(204)	(299)	(295)	(121)
Investing						
Capital expenditure	(9)	(8)	(16)	(50)	(15)	(10)
Acquisition of subsidiaries/ investments	9	0	0	0	0	0
Net proceeds from disposal of short-term	119	(104)	(435)	300	300	0
investments Others	0	(14)	145	0	0	0
Net cash from investing	119	(125)	(306)	250	285	(10)
Financing						
Dividend paid	(1)	(1)	(10)	0	0	0
Net borrowings	(0)	0	(1)	0	0	0
Proceeds from share issues	0	319	717	0	0	0
Share repurchases	(0)	(13)	(27)	0	0	0
Others	0	(8)	(30)	0	0	0
Net cash from financing	(1)	296	650	0	0	0
Net change in cash						
Cash at the beginning of the year	86	121	236	378	329	319
Exchange difference	(2)	6	2	0	0	0
Cash at the end of the year	121	236	378	329	319	188
GROWTH	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec						
Revenue	(4.3%)	11.3%	56.2%	23.4%	17.3%	29.4%
Gross profit	(36.2%)	(11.8%)	148.1%	28.9%	40.1%	55.4%
PROFITABILITY	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec				-		
Gross profit margin	21.8%	17.3%	27.5%	28.7%	34.3%	41.2%
Operating margin	(71.4%)	(86.3%)	(92.2%)	(75.4%)	(59.1%)	(18.6%)
Return on equity (ROE)	(30.6%)	(29.9%)	(22.7%)	(36.2%)	(53.2%)	(30.6%)
GEARING/LIQUIDITY/ACTIVITIES	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec						
Net debt to equity (x)	(0.6)	(0.8)	(1.0)	(1.0)	(0.9)	(0.8)
Current ratio (x)	2.8	3.4	3.9	2.7	1.7	1.4
Receivable turnover days	72.7	70.5	66.1	66.1	66.1	66.1
Inventory turnover days	32.5	34.8	39.2	35.0	35.0	35.0
Payable turnover days	56.5	53.8	51.4	55.0	55.0	55.0
VALUATION	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec						
P/B	na	na	5.6	2.9	4.6	5.7

 $Source: Company \ data, CMBIGM \ estimates. \ Note: The \ calculation \ of \ net \ cash \ includes \ financial \ assets.$ 



# **Disclosures & Disclaimers**

### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

### **CMBIGM Ratings**

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (l)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.